# US 8,785,439 B2 · 2,5,7-substituted oxazolopyrimidine derivatives

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,785,439 B2
- Document ID: US8785439B2
- Status: Granted
- Kind: B2
- Application number: 13/521,823
- Filed: 2011-01-12
- Published: 2013-05-30
- Granted: 2014-07-22
- Earliest claimed: 2010-01-13
- Assignees: Sanofi
- Applicants: Dieter Kadereit; Matthias Schaefer; Stephanie Hachtel; Axel Dietrich; Thomas Huebschle; Andreas Gille; Katrin Hiss
- Inventors: Dieter Kadereit; Matthias Schaefer; Stephanie Hachtel; Axel Dietrich; Thomas Huebschle; Andreas Gille; Katrin Hiss
- Web page: https://patentgrep.com/patent/US8785439B2

## CPC

- C07D 498/04: Ortho-condensed systems
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/02: for treating wounds, ulcers, burns, scars, keloids, or the like
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention relates to oxazolopyrimidine compounds of formula (I), where A, R1, R2 and R3 are defined as stated in the claims. The compounds of formula (I) are suitable, for example, for wound healing.

## Claims

### Claim 1

A compound of the formula I,
wherein
A is O;
R1 is selected from (C1-C6)-alkyl;
R2 is selected from phenyl and pryidinyl, wherein the ring nitrogen atom of the pyridinyl can carry an oxy substituent, and wherein the phenyl and pyridinyl are optionally substituted on one or more ring carbon atoms by identical or different substituents R22;
R3 is selected from (C3-C7)-cycloalkyl-CuH2u— and Het-CvH2v—, wherein u and v are selected from 1 and 2, or R3 is a residue of a saturated or unsaturated, 3-membered to 10-membered, monocyclic or bicyclic ring which comprises 0, 1, 2, 3 or 4 identical or different ring heteroatoms selected from N,O and S, wherein one or two of the ring nitrogen atoms can carry a hydrogen atom or a (C1-C4)-alkyl substituent and one or two of the ring sulfur atoms can carry one or two oxo groups, and wherein the residue of a ring is optionally substituted on one or more ring carbon atoms by identical or different substituents R31;
R22 is selected from halogen, hydroxy, (C1-C4)-alkyl-, (C1-C4)-alkyloxy, and oxy;
R31 is selected from halogen, (C1-C4)-alkyl, (C3-C7)-cycloalkyl, hydroxy, (C1-C4)-alkyloxy, oxo, (C1-C4)-alkyl-S(O)m—, amino, (C-C4)-alkylamino, di((C1-C4)-alkyl)amino, (C1-C4)-alkylcarbonylamino, (C1-C4)-alkylsulfonylamino, nitro, cyano, (C1-C4)-alkylcarbonyl, aminosulfonyl, (C1-C4)-alkylaminosulfonyl and di((C1-C4)-alkyl)aminosulfonyl;
Het is a residue of a saturated, 4-membered to 7-membered, monocyclic heterocycle which comprises 1 or 2 identical or different ring heteroatoms selected from N, O and S and which is bonded via a ring carbon atom, wherein the residue of a heterocycle is optionally substituted by one or more identical or different substituents selected from fluorine and (C1-C4)-alkyl;
m is selected from 0, 1 and 2, wherein all numbers m are independent of each other;
wherein all cycloalkyl groups, independently of each other and independently of any other substituents, are optionally substituted by one or more identical or different substituents selected from fluorine and (C1-C4)-alkyl; and
wherein all alkyl, CuH2u, and CvH2v, groups, independently of each other and independently of any other substituents, are optionally substituted by one or more fluorine substituents,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A process for the preparation of a compound of the formula I as claimed in claim 1, comprising reacting a compound of the formula II with a compound of the formula III,
wherein the groups A, R1, R2 and R3 in the compounds of the formulae II and III are defined as in the compounds of the formula I and additionally functional groups can be present in protected form or in the form of a precursor group, and the group Alk is (C1-C4)-alkyl.

### Claim 3 (depends on 1)

A pharmaceutical composition, comprising at least one compound of the formula I as claimed in claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 4 (depends on 3)

A method of treating wound healing disorders in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 3.

### Claim 5 (depends on 3)

A method of wound healing in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 3.

### Claim 6 (depends on 3)

A method of wound healing in diabetics in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 3.

### Claim 7 (depends on 3)

A method of treating diabetic foot syndrome in a patient in need thereof comprising administering to said patient a therapeutically effective amount of the pharmaceutical composition of claim 3.

### Claim 8 (depends on 4, 5, 6, 7)

The method of any one of claims 4 to 7, wherein the patient is a human.